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Objectives: In this in vitro study, we determined whether meso-tetraphenyl chlorin disulphonate (TPCS2a)-based photochemical delivery
of bleomycin was able to potentiate the cytotoxicity of bleomycin on bladder cancer cells.
Materials and methods: The human RT4, RT112, 253J, T24, and rat AY-27 urothelial carcinoma cell lines were used. Cells were
seeded in 96-well plates. TPCS2a was added to the growth medium and the plates were incubated overnight. Cells were then resuspended in
TPCS2a-free culture medium and incubated for 3 hours. Subsequently, cells were treated for 60 minutes with increasing doses of epirubicin,
gemcitabine, mitomycin C, or bleomycin followed by illumination for different periods. Cell viability was measured with a colorimetric
assay after 72 hours.
Results: For the single treatments, in all 5 cell lines a dose-dependent inhibition of cell proliferation was observed. This was seen both
after treatment with TPCS2a-based photodynamic therapy (PDT), as well as after treatment with either bleomycin or one of the control
chemotherapeutic agents.
After treatment with PDT (240-s illumination), bleomycin 9.0 mM, and the combination of these treatments, relative survival percentages
were 89.2  13.0, 70.2  8.9, and 30.5  6.1, respectively, in the T24 cell line. After treatment with PDT (120-s illumination), bleomycin
27 mM and the combination of these treatments, relative survival percentages were 93.6  15.7, 74.7  9.6, and 30.0  11.1, respectively,
in the AY-27 cell line. In both cell lines, PDT combined with bleomycin showed signiﬁcantly (Po 0.001) higher cell kill than the sum of
the single treatments, suggesting a photochemical internalization effect.
Conclusions: TPCS2a-based photochemical internalization of bleomycin showed a signiﬁcant, at least, additive antiproliferative activity
against human and rat urothelial carcinoma cells in vitro. Thus, photochemical internalization may have therapeutic potential as an
intravesical strategy against bladder cancer. As the effect is heterogeneous, biomarker studies are warranted to be able to predict the effects
of a photochemical internalization–based treatment. r 2014 Elsevier Inc. All rights reserved.
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The initial treatment of non–muscle invasive bladder
cancer (NMIBC) is transurethral resection, followed by
intravesical therapy (i.e., chemotherapy or immunotherapy)
[1]. However, intravesical therapy is not without toxicity,
and a substantial percentage of treated patients still expe-
riences tumor recurrences or progression to muscle-invasivematter r 2014 Elsevier Inc. All rights reserved.
.urolonc.2013.07.005
. Tel.: þ31-24-3613735; fax: þ31-24-3541031.
tsen@gmail.com (H.C. Arentsen).bladder cancer. Therefore, improved treatment modalities
are urgently needed.
Photodynamic therapy (PDT) is a potential treatment
modality for NMIBC. PDT involves the administration of a
photosensitizer and its subsequent activation by light of
an appropriate wavelength. The result is the destruction of
cells containing the photosensitizer. Clinical trials with
PDT have shown promising results in the treatment of
bladder cancer [2,3]. Photochemical internalization (PCI) is
a new technology that can be regarded as an enhanced
PDT modality. PDT and PCI share many fundamental
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drug-delivery system by triggered release of endocytosed
macromolecules into the cytosol [4,5]. Thus, PCI can help
therapeutic molecules reach their intracellular target of
action, realizing their therapeutic potential, instead of being
degraded by lysosomal hydrolases. The PCI effect is
achieved by photosensitizing compounds speciﬁcally local-
izing in the membranes of endocytic vesicles, destroying
these membranes by an oxidative process after illumination.
Bleomycin is used in multiple, standard cancer chemo-
therapy regimens, it has also been studied as intravesical
treatment for NMIBC with only limited success [6,7]. The
hydrophilic and relatively large chemical structure limits the
ability of bleomycin to penetrate membranous structures, but in
many cell types bleomycin can be taken up by endocytosis. In
this case, bleomycin accumulates in endocytic vesicles, where it
may be degraded; or it can enter slowly into the cytosol, where
it can be degraded by bleomycin hydrolase before reaching its
therapeutic target in the nucleus. However, bleomycin cytotox-
icity is highly increased when the cytosol is exposed to similar
amounts of bleomycin following electroporation [8]. Thus,
bleomycin may become a very efﬁcient and speciﬁc chemo-
therapeutic agent when it is combined with a treatment
modality that activates its therapeutic potential only in the
target environment. PCI of bleomycin inhibits tumor growth in
different animal tumor models in a synergistic fashion [9,10].
Firstly, as bladder cancer is potentially well suited for
effective treatment by PCI because it is easily accessible for
both intravesical instillation and illumination, we studied
the relative cell-kill effect of meso-tetraphenyl chlorin
disulphonate (TPCS2a)-based PDT [11] in 4 human bladder
cancer cell lines and a rat bladder cancer cell line
(anticipating future animal studies). Secondly, we studied
whether TPCS2a-based photochemical delivery of bleomy-
cin potentiated the cytotoxicity of bleomycin on these
bladder cancer cell lines. Three commonly used antibladder
cancer intravesical chemotherapeutic agents (i.e., epirubicin,
gemcitabine, and mitomycin C) were used as controls.2. Materials and methods
2.1. Cell lines and culture conditions
The human urothelial carcinoma (UC) cell lines RT4,
RT112, 253J, T24 [17], and rat UC cell line AY-27 (kindly
provided by Dr. Ronald Moore, University of Alberta and
Cross Cancer Institute, Edmonton, Alberta, Canada) were
grown as a monolayer culture in RPMI-1640 medium with
L-glutamine (Invitrogen, Carlsbad, CA), supplemented with
10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO),
penicillin G (100 U/ml), and streptomycin (100 μg/ml)
(Invitrogen) at 371C in a humidiﬁed 95% air/5% carbon
dioxide atmosphere. Medium was changed twice weekly
and cells were passaged using trypsin ethylenediaminetetra-
acetic acid (Invitrogen) when conﬂuent.2.2. Chemotherapeutic- and TPCS2a-based PDT
experiments
For TPCS2a-based photodynamic treatments, cells were
harvested, washed, resuspended and plated at 1.0  104
cells per well in 96-well microtiter plates (Corning Inc.
Corning, New York; black plate, clear bottom). TPCS2a,
(supplied by PCI Biotech AS, Oslo, Norway) was added at
a ﬁnal concentration of 0.2 mg/ml, and the plates were
incubated overnight. Cells were then washed 3 times with
TPCS2a-free culture medium, resuspended in TPCS2a-free
culture medium and incubated for 4 hours. Cells were then
illuminated for different periods (0–10 min), using a Lumi-
Source illumination device (PCI Biotech AS, Oslo,
Norway). LumiSource was delivered with a bank of 4 light
tubes (4  18 W Osram L 18/67, Blue) emitting mainly
blue light with a peak wavelength of approximately
420 nm, with an average irradiance of 13.5 mW/cm2.
For combination therapy experiments, cells were pre-
pared as described previously and after incubation in
TPCS2a-free culture medium for 3 hours, cells were sub-
sequently exposed to increasing doses of epirubicin (Pﬁzer
bv, Capelle a/d IJssel, The Netherlands) (0–48.6 mM),
gemcitabine (Sun Pharmaceutical Industries Europe B.V.,
Hoofddorp, The Netherlands) (0–65.6 mM), mitomycin C
(Kyowa Hakko Kirin Co Ltd., Tokyo, Japan) (0–65.6 mM),
or bleomycin (Euro Nippon Kayaku GmbH, Frankfurt,
Germany) (0–81.0 mM). All solutions were prepared on
the day of use. After incubation for 1 more hour, the cells
were illuminated for different periods (0–5 min) as
described earlier. After illumination, cells were washed 3
times with culture medium. Cell proliferation was measured
after 72 hours. Treatment doses used in these studies were
selected to evaluate whether additive effects occurred and
were not optimized for treatment outcome.
2.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) assay
The effect of chemotherapy and PCI was determined by
MTT assay. After 72 hours of treatment, 30 μl of 5 mg/ml
MTT solution (Sigma-Aldrich) prepared in phosphate-
buffered saline was added to the medium. Blue dye taken
up by the cells after 4 hours of incubation was dissolved in
dimethyl sulfoxide (100 μl per well) and optical density at
595 nm was read on an automated microplate reader
(BioRad 3550, BioRad Laboratories, Hercules, CA). The
bleomycin experiments were performed in quadruplicate
and repeated one time by another laboratory worker; the
control experiments with epirubicin, gemcitabine, and
mitomycin C were performed at least once in quadruplicate.
2.4. Statistical analysis
In each combination experiment (with epirubicin, gem-
citabine, mitomycin C, and bleomycin), the Wald test was
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relative cell survival between the treatment groups (control,
PDT alone, chemotherapy alone, and combination).
Po 0.05 was considered statistically signiﬁcant.3. Results
3.1. Chemotherapeutic- and TPCS2a-based PDT single
treatment effects
PDT alone showed a clear phototoxic illumination time-
dependent inhibition of cell proliferation in all 5 cell lines
(Fig. 1). The viability of all cell lines was reduced to o40%
of control with 360-second illumination. A further increase
of the light dose resulted in approximately 99% cell death at
600 seconds (data not shown).
TPCS2a pretreatment followed by chemotherapy treat-
ment alone (without illumination) demonstrated a clear
dose-dependent inhibition of cell proliferation in all 5 cell
lines tested (Fig. 2).
3.2. Chemotherapeutic- and TPCS2a-based PDT
combination effects
To evaluate the PCI therapy effect, chemotherapy was
combined with TPCS2a and light treatment (Fig. 2). Combi-
nation of PDT and bleomycin was clearly superior to the
single treatment modalities in the human T24 cell line and
the rat AY-27 cell line, indicating at least an additive effect,
suggesting a PCI effect. In contrast, additive treatment
effects were observed for the other treatment regimens and
in the other cell lines, as indicated by the parallel dose-
response curves.
The treatment effects of PDT combined with bleomycin
and PDT combined with epirubicin, gemcitabine, or mito-
mycin C in the T24 and AY-27 cell lines are shown inFig. 1. Relative survival of human 253J, RT4, RT112, and T24 and rat
AY-27 urothelial carcinoma cells after TPCS2a-based photodynamic
treatment. The cells were incubated with TPCS2a at 0.2 mg/ml for 24
hours, washed and incubated for 4 more hours in TPCS2a-free culture
medium and subsequently illuminated. Relative cell survival was assessed
72 hours later. The percentage (mean  SD) of viable cells from the
corresponding control is shown. SD ¼ standard deviation.Fig. 3. To be able to compare the 4 individual chemo-
therapeutic agents, we selected the chemotherapeutic doses
with a relative cell survival of470%: epirubicin 5.4 mM,
gemcitabine 0.8 mM, mitomycin C 65.6 mM, and bleomycin
9.0 mM for the T24 cell line and epirubicin 0.2 mM,
gemcitabine 0.3 mM, mitomycin C 0.8 mM, and bleomycin
27 mM for the AY-27 cell line. As shown in Fig. 3, PDT
combined with any chemotherapeutic drug showed a
signiﬁcantly higher cell kill compared with PDT alone in
both cell lines (Po 0.05). Similarly this combination was
superior to chemotherapy alone (Po 0.05), except for
epirubicin and gemcitabine treatment in the AY-27 cell
line. PDT combined with bleomycin showed signiﬁcantly
(Po 0.001) higher cell kill than the sum of the single
treatments in both cell lines, suggesting a PCI effect.4. Discussion
In this in vitro study, we evaluated the therapeutic
potential of TPCS2a-based photochemical delivery of bleo-
mycin in 4 human bladder cancer cell lines and a rat bladder
cancer cell line. In the T24 and AY-27 cell lines, a
signiﬁcant and at least additive antiproliferative effect of
the combined PDT and bleomycin treatment was observed,
a clear indication of the PCI effect. For all the single
treatment regimens, a clear dose-dependent inhibition of
cell proliferation was observed for all 5 cell lines.
Chemotherapeutics require efﬁcient penetration into the
cytosol of the tumor cells to reach their intracellular targets
and exert their therapeutic activity. The prerequisite to
penetrate the plasma membrane limits the exploitable
chemical structure of chemotherapeutic agents to mostly
small and lipophilic compounds penetrating the plasma
membrane by passive diffusion. In addition, drugs (also
more hydrophilic drugs) can be taken up by means of
various transporters, e.g., gemcitabine [12].
The PDT mechanism relies on the in situ generation of
cytotoxic agents by the activation of a light-sensitive drug,
resulting in cell death [13]. The PCI technology is based on
the same principles as PDT, i.e., the activation of a
photosensitizer by light followed by formation of reactive
oxygen species. Unlike PDT, the concept of PCI is based on
the use of designed photosensitizers that localize preferen-
tially in the membranes of endocytic vesicles of the targeted
cells. The most efﬁcient PCI photosensitizers have an
amphiphilic structure (e.g., TPCS2a [11]) with a hydrophilic
part inhibiting penetration through cellular membranes. The
site-speciﬁc PCI-induced drug delivery adds to the well-
described cytotoxic [13], vascular, and immunostimulatory
effects of PDT. PCI of bleomycin has already shown to
induce a synergistic inhibition of tumor growth in vivo
[9,10]. Adigbli et al. [14] demonstrated an increased
cytotoxic (i.e., PCI) effect of the chemotherapeutic agent,
mitoxantrone, combined with the photosensitizer hypericin
and illumination against multidrug-resistant bladder cancer
Fig. 2. Relative survival of human 253J, RT4, RT112, and T24 and rat AY-27 urothelial carcinoma cells after TPCS2a-based photodynamic treatment in
combination with epirubicin, gemcitabine, mitomycin C, or bleomycin. The cells were incubated with TPCS2a at 0.2 mg/ml for 24 hours, washed and incubated
for 3 more hours in TPCS2a-free culture medium and subsequently treated with an increasing dose of epirubicin, gemcitabine, mitomycin C, or bleomycin. After
incubation for 1 more hour, the cells were illuminated with increasing illumination times (0–300 s). Cells were then washed and incubated again. Relative cell
survival was assessed 72 hours later. The percentage (mean  SD) of viable cells from the corresponding control is shown. The curves with 0 seconds of
illumination represent the dose-response curves after treatment with chemotherapy alone. SD ¼ standard deviation.
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Fig. 3. TPCS2a-based photodynamic therapy in combination with epirubicin, gemcitabine, mitomycin C, and bleomycin in the human T24 cell line and the rat
AY-27 cell line. The highest chemotherapeutic doses (for chemotherapy alone) with a relative cell survival of470% were selected, i.e., epirubicin 5.4 mM,
gemcitabine 0.8 mM, mitomycin C 65.6 mM, and bleomycin 9.0 mM in the T24 cell line and epirubicin 0.2 mM, gemcitabine 0.3 mM, mitomycin C 0.8 mM,
and bleomycin 27 mM in the AY-27 cell line. The chemotherapy bars represent the relative cell survival percentages after treatment with these doses. The PDT
bars represent the relative cell survival percentage in the combination experiments (without chemotherapeutics) after 240-second illumination in the T24 cell
line and after 120 seconds in the AY-27 cell line. These illumination times were selected because with these light doses the differences in relative cell survival
are most clear. The combination therapy bars represent the relative cell survival percentages after the combination treatment with the selected chemotherapy
and light doses. With these doses, any further added toxicity from the combination therapy can be detected and a comparison of the different combinations can
be made. Each bar represents the percentage (mean þ SD) of viable cells from the corresponding control. * Po 0.001, compared with the sum of the single
treatments. SD ¼ standard deviation.
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systemic side effects of anticancer cytotoxic agents by
reducing the drug dose required for a given effect and by
conferring an increased level of treatment selectivity as the
cytotoxic effect would be greatest in areas that are
illuminated, decreasing systemic toxicity [15], in line with
our observations.
A prerequisite for PCI is that the molecule of interest
is accumulated in endocytic vesicles at some stage in
the process. We cannot preclude that our results are the
consequence of off-target effects as internalization of the
chemotherapeutics was not studied here. However, bleomy-
cin is a widely used chemotherapeutic agent for several
types of cancer (e.g., testicular cancers, malignant lympho-
mas and squamous cell carcinomas of the cervix, and head
and neck cancers), with endocytosis being an important
uptake mechanism [8], probably because of its hydrophilic
and relatively large chemical structure (molecular weight:
1,415.6 Da). Thus, not unexpectedly we observed the most
pronounced PCI effects with bleomycin. The lower PCI
effects seen for the other chemotherapeutics are most likely
the consequence of their lower molecular weight and higher
hydrophobicity, or their cellular uptake is dependent on the
activity of transport proteins, promoting easier cytoplasmic
accumulation.
Only in the T24 and AY-27 cell lines, the treatment
effects of PDT combined with bleomycin were signiﬁcantly
higher than the sum of the single treatments. The hetero-
geneous response of the bladder cancer cell lines is
probably a reﬂection of the heterogeneity of the disease.
It is possible that the endocytosis and transport mechanisms
of bleomycin or TPCS2a or both differ between the various
cell lines. It has been well established that the cytotoxic
effect of bleomycin varies widely between different tumorsas well as between different organs [16]. This might be due
to differences in the cells’ DNA-repair capacity, bleomycin
hydrolase activity, cellular uptake mechanisms, and possi-
bly the rate of bleomycin efﬂux. In our experiments,
TPCS2a represents an additional element. It is possible that
different cell types use different endocytosis pathways
leading to intracellular TPCS2a accumulation resulting in
cell death without endosomal release. Another possible
factor for the heterogeneous antiproliferative effects are
the cellular resistance mechanisms to bleomycin. A better
understanding of tumor biology and pathways critical for
tumor genesis may provide personalized treatment oppor-
tunities for patients with urothelial cancer.
In conclusion, TPCS2a-based PCI of bleomycin showed
a signiﬁcant, at least, additive antiproliferative activity
against human and rat UC cells in vitro. Therefore, PCI
may have therapeutic potential as an intravesical strategy
against NMIBC, provided patient stratiﬁcation can be
achieved based on a predictive biomarker (panel). Further
studies are needed to explore whether such predictive
biomarkers can be deﬁned.References
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